BerGenBio to Present Clinical Data From Phase II Combination Trial of Bemcentinib and LDAC Trial in Elderly AML Patients at ASH 2019
The poster will provide an update on its phase II study of bemcentinib (BGB324) in combination with Low-dose Cytarabine in elderly AML patients.
Abstract titles have been announced online. Details of the presentation are below.
Title: Durable responses observed in elderly AML patients unfit for intensive chemotherapy with first-in class selective AXL inhibitor bemcentinib (BGB324) in combination with LDAC: Phase II open-label study
Date: Monday
Session
Time, Location:
About AXL
AXL kinase is a cell membrane receptor and an essential mediator of the biological mechanisms underlying life-threatening diseases. In cancer, AXL suppresses the body's immune response to tumours and drives cancer treatment failure across many indications. AXL inhibitors, therefore, have potential high value at the centre of cancer combination therapy, addressing significant unmet medical needs and multiple high-value market opportunities. Research has also shown that AXL mediates other aggressive diseases.
About bemcentinib
Bemcentinib (formerly known as BGB324), is a potentially first-in-class selective AXL inhibitor in a broad phase II clinical development programme. Ongoing clinical trials are investigating bemcentinib in multiple solid and haematological tumours, in combination with current and emerging therapies (including immunotherapies, targeted therapies and chemotherapy), and as a single agent. Bemcentinib targets and binds to the intracellular catalytic kinase domain of AXL receptor tyrosine kinase and inhibits its activity. Increase in AXL function has been linked to key mechanisms of drug resistance and immune escape by tumour cells, leading to aggressive metastatic cancers.
About
Contacts
+47 917 86 304
+47 917 86 513
International Media Relations
+44 20 3709 5700
Media Relations in
+47 995 13 891
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
View original content:http://www.prnewswire.com/news-releases/bergenbio-to-present-clinical-data-from-phase-ii-combination-trial-of-bemcentinib-and-ldac-trial-in-elderly-aml-patients-at-ash-2019-300953783.html
SOURCE
NHI Announces Fourth Quarter 2019 Dividend
Inside Pete Buttigieg’s Iowa Surge
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News